Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | IRAK1 | P51617 | 8/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22987489 | 0.85 | ADORA3 (0.48) | ADORA3EPHX2IRAK4ADORA2AADORA1 | |
| SCHEMBL22987482 | 0.84 | ADORA3 (0.38) | ADORA3EPHX2IRAK4ADORA2AADORA1 | |
| SCHEMBL22987454 | 0.84 | ADORA3 (0.38) | ADORA3EPHX2IRAK1IRAK4ADORA2A | |
| SCHEMBL22987558 | 0.84 | HSP90AB1 (0.41) | ADORA3EPHX2IRAK1IRAK4PIK3CD | |
| SCHEMBL22988066 | 0.83 | ADORA3 (0.38) | ADORA3CREBBPIRAK1IRAK4PIK3CD | |
| SCHEMBL22988032 | 0.81 | CNR1 (0.39) | ADORA3PIK3CD | |
| SCHEMBL22987840 | 0.81 | ADORA3 (0.43) | ADORA3ADORA2AADORA1 | |
| SCHEMBL22987472 | 0.81 | PDE10A (0.39) | ADORA3EPHX2IRAK1IRAK4ADORA2A | |
| SCHEMBL22987839 | 0.80 | PDE10A (0.39) | ADORA3PDE10A | |
| SCHEMBL22978978 | 0.78 | ADORA3 (0.49) | ADORA3ADORA2AADORA1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| WO-2021028382-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | AHR, HRH4, HRH1 | ADORA3 34/4885CREBBP 2500/4885EPHX2 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.